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Abstract 
Background 
The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular 
thrombosis and/or pregnancy morbidity, associated with a persistent positivity for antiphospholipid 
antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus 
anticoagulant (LA), anticardiolipin (aCL) and anti-β2 glycoprotein-I (β2GPI).  To date, the 
therapeutic approach for thrombotic APS mainly centers on long-term anticoagulation with vitamin 
K antagonist (VKA).  
Purpose of the review 
APS management may represent a challenge for the treating physicians. Patients with different aPL 
profiles need a tailored risk-stratified approach. Besides, in patients with recurrent thrombotic 
events despite therapy with VKA or those with microvascular involvement new therapeutic options 
are highly needed. 
In this review we aim to elucidate recent findings about new aPL specifities, available risk scoring 
models and novel therapeutic approaches in APS management.  
. 
1. Intro 
The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular 
thrombosis (arterial and/or venous) and/or pregnancy morbidity (miscarriages, fetal deaths, 
premature births, and late pregnancy complications) associated with a persistent positivity for 
antiphospholipid antibodies (aPL). The current classification criteria for APS include three 
laboratory tests: lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2 glycoprotein-I 
(β2GPI). However, growing evidences are supporting that in some selected cases non-criteria aPL 
might also play a role. To prevent detection of transient antibodies, tests must be positive ≥ 2 
occasions, at least 12 weeks apart. 
Herewith, we aim to discuss new insights in APS, including laboratory testing, thrombotic risk 
assessment and upcoming therapeutic options.  
2. Role of new antibodies specificities  
In the current clinical practice, aCL, anti-β2GPI antibodies and the LA have been the most 
established tests for the diagnosis of APS1. The clinical utility of aPL assays for autoantibodies 
other than the routinely used is currently under debate. Indeed, current lines of research are 
examining the usefulness of testing for new aPL specificities in identifying APS in patients with 
thrombosis and/or pregnancy morbidity, particularly in those who are repeatedly negative for the 
criteria aPL. Among the so called extra-criteria aPL tests, anti-phrothrombin (and mainly anti-
phophosphatidylserine/prothrombin, aPS/PT) antibodies and anti-β2GPI glycoprotein-I Domain 1 
antibodies, have been proposed to potentially improve the diagnostic accuracy and, especially when 
assessing the risk for both thrombosis and pregnancy morbidities in patients suspected of APS. 
2.1 Anti-β2GPI glycoprotein-I Domain 1 antibodies 
Although the physiological functions of β2GPI are still uncertain, available evidence supports a 
pathogenic role for anti-β2GPI antibodies contributing to thrombosis and pregnancy morbidity. 
However, not all patients positive for the presence of anti-β2GPI antibodies develop clinical aPL-
related manifestations. This heterogeneity in the pathogenic potential of anti-β2GPI antibodies 
might be ascribed to the molecular structure of β2GPI, presenting multiple antigenic specificities 
that can be targeted by different autoantibodies. The β2GPI has five homologous domains (D1 to 
D5) and the main epitope that has been found to be associated with APS involves regions of D1 and 
growing evidence, both in vivo and in vitro, has resulted in the identification of domain I as the 
“immunodominant epitope”2, supporting a role for anti β2GPI-DI antibodies in the development of 
APS-related clinical manifestations. 
Recently, a systematic review and meta-analysis that included a total of 1585 patients, reported an 
overall estimated median prevalence of anti β2GPI-DI antibodies of 44,3% in patients with APS 
and/or systemic lupus erythematosus (SLE) and a significant higher prevalence of anti-β2GPI-DI 
antibodies among APS patients compared to SLE alone3. Furthermore, when analyzing the 
thrombotic risk assessment associated with anti β2GPI-DI antibodies positivity, the study reported 
an overall OR 1,99; 95% CI 1,52-2,6; p<.0001. Anti-β2GPI-DI antibodies might represent a 
promising tool when assessing thrombotic risk in APS patients. 
2.2 Antiprothrombin and anti-phosphatidylserine/prothrombin antibodies  
Antiprothrombin (aPT) and aPS/PT antibodies are directed against negatively charged 
phospholipids other than cardiolipin. aPT antibodies are commonly detected by ELISA, using 
prothrombin coated onto irradiated plates, or prothrombin in complex with phosphatidylserine. 
Although aPT and aPS/PT antibodies can co-exist in the same patients, they are part of two 
different populations of autoantibodies. Currently, most of the studies in the literature support their 
role in helping defining APS diagnosis, as well as the association between antiprothrombin 
antibodies, in particular aPS/PT , and the clinical manifestations of APS4. Although existing data is 
promising, further studies are needed in order to establish the real impact and clinical significance 
of these antibodies in routine testing.  
3. Risk assessment and aPL 
When assessing risk for clinical manifestations of APS, aPL titres as well as their single, double or 
triple presence, have all been suggested to have a different distinct significance5. In general, the 
presence of aPL in individuals without any clinical manifestations, i.e. aPL carriers, can be seen as a 
risk factor for first time thromboembolic events and various studies investigated the significance of 
aPL positivity and the occurrence of thrombotic events6.  
In more detail, LA has been shown to be a better predictor for thrombosis compared to any other 
aPL, as described by a systematic review in 2003 by Galli et al., including 753 patients and 234 
controls, that showed that LA is a strong risk factors for both arterial and venous thrombosis6. On 
the other hand, De Groot et al. showed in their Leiden cohort that included 473 patients and 472 
control subjects, that the presence of LA alone without the presence of anti-β2GPI (or 
antiprothrombin antibodies) was not significantly associated with a risk for a first deep vein 
thrombosis (DVT) (OR 1.3, 95 % CI 0.3–6.0). However, in patients who tested positive for LA and 
anti-β2GPI antibodies (or antiprothrombin) the OR of a first time deep venous thrombosis increased 
to 10.1 (95 % CI 1.3–79.8)7.  
Regarding triple positivity, Pengo et al. demonstrated the association of triple positive patients 
carries with an increased risk of clinical manifestations of APS, both thrombosis and adverse 
pregnancy outcome, compared to patients with positivity for only one aPL8. 
Otomo et al. expanded on this principle and developed the aPL-score (aPL-s), in order to determine 
whether aPL titres influence the risk of thrombosis, comparing high to medium/low titres of aCL 
and anti-β2GPI IgG and IgM, respectively. The group showed that high levels of IgG aCL, anti-
β2GPI (and also antiphosphatidylserine and antiprothrombin antibodies) were closely related to the 
clinical manifestations of APS. In their study the aPL-score related with a history of thrombosis or 
pregnancy morbidity. Moreover, the aPL-s score was shown to be of predictive value for the 
recurrence and/or new onset of thrombotic events.  
In conclusion, different aPL profiles are an important indicator for risk assessment of APS clinical 
manifestations and represent a fundamental tool for clinicians especially when managing aPL 
carriers.  
3.1 Global APS Score (GAPSS) 
Moving towards the concept of aPL as a risk factor, our group recently published a comprehensive 
series of studies developing and validating the global APS score (GAPSS) in different patients 
populations9. The GAPPS score combines independent risk factors for thrombosis and pregnancy 
loss, taking into account aPL profiles (criteria aPL and non-criteria aPL), as well as conventional 
cardiovascular risk factors and autoimmune antibody profiles. Among all the computed variables 
(extensive aPL testing, cardiovascular risk factors evaluation, autoimmune profile), multivariate 
logistic regression analysis showed that only arterial hypertension, hyperlipidaemia, LA, aCL IgG 
and/or IgM, anti-β2GPI IgG and/or IgM and aPS/PT IgG and/or IgM were independent risk factors 
for thrombosis and/or pregnancy morbidity.  
In brief, all variables were computed as dichotomized, in order make GAPSS more widely 
adoptable. aPL positivity was assessed according to the updated APS classification criteria1. The 
GAPSS includes IgG/IgM aCL (five points), IgG/ IgM anti-β2GPI (four points), LA (four points), 
IgG/IgM anti-phosphatidylserine-prothrombin complex antibodies (three points), hyperlipedaemia 
(three points) and arterial hypertension (one point).  
The GAPSS model was developed in patients with SLE and higher GAPS scores were observed in 
patients who experienced thrombosis and/or pregnancy loss compared with those without clinical 
events. Moreover, the GAPSS score was evaluated in a subsequent prospective study of 51 SLE 
patients10 and in 62 consecutive patients with primary APS10. The GAPSS score was further The 
GAPSS model was further applied and validated by two independent groups that described APS 
manifestations (thrombosis or pregnancy morbidity) were experienced by patients with higher 
GAPSS values compared to patients without APS manifestations10. 
4. New therapeutic options beyond anticoagulation with Vitamin K antagonists  
Long-term anticoagulation with Vitamin K antagonists (VKA) is currently the therapeutic option 
for thrombotic APS management. Table 1 summarizes the current strategies for management of 
patients with aPL. However, therapy with VKA rises many challenges for clinicians and patients, 
including adherence to treatment, dietary interactions and impacts on daily life. Besides, patients 
with APS might experience clinical manifestations not directly related to thrombotic pathogenesis, 
that may not respond to anticoagulation (e.g., from systemic symptoms such as fatigue to organ 
specific manifestations as cardiac valves involvement). Moreover, the monitoring of anticoagulation 
with VKA in LA positive patients might be challenging, as the responsiveness of the reagents used 
in the INR testing varies widely, leading to potential instability of anticoagulation. For the above 
reasons new therapeutic options for APS management are highly needed.  
4.1 Hydroxychloroquine  
Clinical trials and animal models supported the role of hydroxychloroquine (HCQ) as useful tool to 
reduce the risk of thrombosis11. The various antithrombotic mechanisms include inhibition of 
platelet aggregation and adhesion, cholesterol lowering mechanisms and blockade of aPL 
production11.  
In a recent trial, Rand et al. 12 showed that HCQ significantly reduced both the binding of aPL-
b2GPI complexes to phospholipid surfaces and the binding of the individual proteins to bilayers. 
The same group demonstrated in a further study 12 that HCQ also caused modest, but statistically 
significant, reductions of clinical aPL titers as well as a reduction of the disruption by aPL of the 
annexin A5 anticoagulant shield.  
Both retrospective and prospective studies demonstrated a beneficial effect of HCQ on primary 
thrombosis prevention in aPL-positive patients. More in detail, Kaiser et al.13 enrolled in a large 
cohort of 1930 SLE patients, confirmed that HCQ use was protective for thrombosis. However, a 
recent randomized multicenter study (https://clinicaltrials.gov/ct2/show/NCT01784523) 
investigating the prophylactic role of HCQ against thrombosis in patients with aPL has been early 
terminated due to low recruitment rate exacerbated by manufacturing shortage and price increase of 
HCQ, pointing out the challenges of designing prospective randomized trials in this conditions.  
 
4.2 Rivaroxaban in Antiphospholipid Syndrome (RAPS) 
The use of the novel anticoagulants would be expected to improve the quality of life of APS 
patients. These agents, in fact, have fewer drugs interactions and dietary restrictions compared with 
VKA and very predictable anticoagulants effects with fixed dosing regiments, making it 
unnecessary to routinely monitor anticoagulant intensity. However, the lack of INR monitoring 
could represent a downfall of novel anticoagulant therapy, introducing variability in patients 
adherence.  
Rivaroxaban (a direct anti-X agent) has been approved by the European Medecines Agency for the 
prevention of stroke and systemic embolism in patients with atrial fibrillation and for venous 
thromboembolic events management. RAPS (Rivaroxaban in Antiphospholipid Syndrome) was a 
randomised, controlled, open-label, phase 2/3, non-inferiority trial, that included 116 APS patients 
who were taking VKA for previous venous thromboembolism, with a target international 
normalised ratio of 2.514. Patients were randomized to receive warfarin or 20 mg oral rivaroxaban 
daily. Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin 
generation. Endogenous thrombin potential for rivaroxaban did not reach the non-inferiority 
threshold, but as there was no increase in thrombotic risk compared with standard-intensity 
warfarin. No thrombosis or major bleeding were seen. Serious adverse events occurred in four 
patients. In brief, the first was an intracranial haemorrhage that pre-dated the trial, the second was 
an episode of abdominal pain, vomiting, arthralgia, and myalgia. Two were judged to be unrelated 
to the trial drug: the first was a suspected deep vein thrombosis at day 176, the second was intestinal 
perforation.  
Rivaroxaban could be an effective alternative in patients with APS and previous venous 
thromboembolism. Its use in APS patients with arterial events and/or high risk aPL profile needs 
further investigation. To date, at least other three trials (RAPS-Canada, TRAPS 
(https://clinicaltrials.gov/ct2/show/NCT02157272) and ASTRO-APS 
(https://clinicaltrials.gov/ct2/show/NCT02295475) are currently further investigating the use of 
direct new oral anticoagulants in patients with APS and results are highly waited.  
4.3 IVIG 
Evidences support the efficacy of IVIG in addition to conventional therapy, in primary and 
secondary APS patients, in preventing the occurrence of further thromboembolic events15.  Despite 
the promising observations especially in patients with the so-called APS plus (APS with ANA 
positivity and sign/symptoms of a connective tissue disease not fulfilling the classification criteria) 
further data are need to establish indications and optimal doses of IVIG in thrombotic APS.  
4.4 B-Cells depletion therapy  
While immunosuppressive drugs such as i.v. cyclophosphamide might be helpful in patients with 
active systemic autoimmune disease mainly SLE and systemic vasculitis, their use in APS is still 
controversial and limited to very selected case of catastrophic APS (CAPS) or in severe cases 
refractory to standard therapy. Some case reports about the use of rituximab – an anti-CD20 
monoclonal – in the treatment of APS have been published16.  
B cells are likely to play a central role in the generation of the aPL-induced clinical manifestations 
of the disease, so could constitute a logical therapeutic target in APS. Anecdotally, its use has also 
been associated with a down-regulation of aPL titers17. A pilot open-label phase II trial of RTX for 
noncriteria manifestations of APS (such as thrombocytopenia, skin ulcers, nephropathy and 
cognitive dysfunction) concluded that RTX may represent a well-tolerated option in the therapeutic 
arsenal for APS. However, it has been reported to be effective in controlling some but not all non-
criteria manifestations of APS. Overall, although more data are necessary to support the use of these 
drugs in the setting of severe APS, current experience seems quite promising, especially in patients 
with severe thrombocytopaenia. Table 2 summaries our experience with cyclophosphamide and/or 
rituximab in very life-threating cases refractory to standard therapies. Of note, two patients have 
been treated with an Intensified B-Cell Depletion Therapy (IBCDT), an approach we employed as a 
rescue therapy in refractory lupus nephritis or systemic vasculitis. IBCDT consisting of “four 
(weekly) plus two (monthly) doses” of rituximab (375 mg/sm), associated with two i.v 
administrations of 10 mg/kg cyclophosphamide and three pulses of 15 mg/kg methylprednisolone, 
without further immunosuppressive maintenance therapy. Despite the promising results, this 
approach has been limited to very selected cases and further data are needed to investigate dosage 
and indications.  
4.5 Eculizumab 
Eculizumab is a recombinant full-humanized IgG2/IgG4 monoclonal antibody that blocks the 
formation of the terminal complex sC5b-9 and C5a by binding to the C5 complement component 
and consequently blocking the activation pathway. Growing evidences from in vitro and in vivo 
studies are suggesting a promising role for eculizumab for APS. In fact, the complement can be 
activated by the binding of C3 fragment to the Fc receptor of aPL antibodies. The activation of 
complement pathway and consequently production of inflammatory molecules like C5a by aPL can 
directly activate platelets and monocytes, inducing the coagulation cascade and leading to 
thrombosis. Recently, Durcan and al18 observed in a cohort of 2399 patients that the presence of 
aCL and hypocomplementemia (both low C3 and C4) strongly associates with deep vein 
thrombosis. The presence of LAC and low C4 were also associated with stroke. Therefore, 
eculizumab might represent a valuable therapeutic alternative in APS patients, especially in patients 
with concomitant hypocomplementemia.  
Furthermore, case reports describe the successful use of eculizumab in severe cases of APS, such as 
the catastrophic variant of the syndrome and cases of APS and thrombotic microangiopathy19 
5.Conclusion 
APS remains a substantial diagnostic challenge for physicians, mainly due to the expanding range 
of reported clinical manifestations associated with the presence of aPL as well as to the expanding 
limitations of current laboratory testing. Although it is the physician taking care of the patient who 
ultimately makes the diagnosis, laboratory-testing still plays a key role in many phases of the 
management. While it is widely accepted that aPL play a crucial pathogenic role in inducing clinical 
manifestations, limitations in detailed knowledge by both clinical and laboratory perspectives 
regarding the “complete” range of available aPL tests, as well as ongoing problems with assay 
reproducibility and standardization exist.  
To date, aPL profiling represents the most accurate risk stratification tool for thrombosis. The so 
called “triple positivity” was found to be associated with thrombosis in up to 87% of cases of APS 
while in the other profiles the association was around 50%20. With regard to risk stratification, some 
scoring systems have been proposed to help physicians to identify the individual risk of 
thrombosis/pregnancy morbidity in patients positive for aPL; among others, the GAPSS, which 
brings together the aPL profile (including both criteria and non-criteria aPL) and traditional 
cardiovascular risk factors, seems a promising tool to identify patients at higher risk of new events. 
Referring to treatments, while current therapeutic options remain confined to long-term 
anticoagulation with VKA, the future holds much promise with the identification of novel potential 
targets, many of which are currently under investigation. The challenge will be to design 
prospective randomized controlled clinical trials to provide the evidence necessary to support 
integration of these therapies into clinical practice. Ideally, the task for the future will be to tailor 
the APS management, taking into account aPL profile and clinical manifestations.  
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